0001193125-26-204188
SEC filingCRISPR Therapeutics reported modest revenue growth and a narrowed operating loss in Q1 2026, reflecting increased CASGEVY revenue share under the Vertex collaboration — not commercial sales — while continued heavy R&D investment drove deep negative cash flow from operations.
Revenue for Q1 2026 totaled $1.5M, up 68.6% year-over-year from $865.0K. As stated in Item 2 — Management’s Discussion and Analysis — this increase was attributable to an increase in CRISPR Therapeutics’ share of CASGEVY revenue under its collaboration with Vertex. This reflects contractual revenue allocation mechanics tied to CASGEVY’s global commercial rollout, not direct product sales or new commercial agreements. The company remains wholly dependent on partnership-based revenue streams at this stage.
Operating income improved to -$130.2M from -$148.4M in Q1 2025 — a 12.2% year-over-year improvement in loss magnitude. This narrowing occurred despite sustained investment in research and development, consistent with management’s repeated commentary that operating expenses will remain aligned with those typical for biotech companies of CRSP’s size and clinical-stage profile. No breakdown of R&D or G&A expenses is supported by the authoritative financial packet; therefore, explanations of expense drivers beyond this high-level context are omitted.
Capital expenditures totaled $504K, supporting internal infrastructure — specifically, the GMP manufacturing facility in Framingham, Massachusetts, where zugo-cel is produced for clinical trials. Net cash used in investing activities was not disclosed in the authoritative packet, but management confirmed in Item 2 that increases in marketable securities purchases were the primary driver. Free cash flow — defined as net cash provided by operating activities less capital expenditures — was -$109.4M.
CRISPR Therapeutics continues to operate with cumulative negative cash flows from operations since inception, as noted in Item 2. Management expects operating expenses to persist — and potentially increase — to support advancing clinical programs, regulatory filings, and preparation for potential commercialization. No balance sheet liquidity metrics (e.g., cash balances or runway estimates) are supported by the authoritative packet and are therefore excluded.